Last year in the UK over 60,000 cancer patients enrolled on clinical trials aimed at improving cancer treatments and making them available to all.
A study looking at a new drug to treat low platelet counts in people with low or moderate risk myelodysplastic syndrome (MDS)
This study was to see how well a new injection called romiplostim worked to improve platelet counts in people with myelodysplastic syndrome (MDS).
Myelodysplastic syndromes (MDS) are a group of disorders where too many blood cells are produced by the
If your MDS causes symptoms, you may have chemotherapy, or you may have
- See how well romiplostim worked to treat low platelets in people with MDS
- Find out more about the side effects
Summary of results
The committee that monitors the safety and design of the trial (the data monitoring committee) recommended that this trial was changed. This was because early results suggested that the possible benefit of romiplostim did not outweigh the possible risk (due to a temporary increase in the number of immature cells called blast cells), of people with MDS being diagnosed with, and treated for AML. So the trial was stopped.
How to join a clinical trial
Prof David Bowen
Experimental Cancer Medicine Centre (ECMC)